ReviewJournal of clinical medicine2021
Clinical Management of Moyamoya Patients.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Risk of post-revascularization stroke in Moyamoya disease: A systematic review, meta-analysis, and meta-regression.Neurosurgical review · 2026Pooled it
- Angiographic outcomes after indirect revascularization in pediatric Moyamoya disease: a systematic review and Meta-analysis.Neurosurgical review · 2026Pooled it
- An unusual presentation of Moyamoya disease managed conservatively in a resource limited region: A case report.Radiology case reports · 2026Article
- Vessel wall imaging in adult moyamoya disease with presumed acute in situ thrombotic occlusion: illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
- Moyamoya Disease in Pregnancy: A Case Series.AJP reports · 2026Article
- Late-Onset Moyamoya Disease Presenting With Acute Hemiparesis in a 77-Year-Old Patient: A Case Report.Cureus · 2026Article
- Article
- Neurological Complications in Children with Moyamoya Disease-Case Report and Literature Review.Journal of clinical medicine · 2026Article
- Short-TR Acquisition Time-of-flight MR Angiography with Deep Learning Reconstruction: Technical Feasibility and Initial Clinical Evaluation in Moyamoya Disease.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Article
- Neurovascular Issues in Neurofibromatosis Type I: Focus on Intracranial Stenosis.Life (Basel, Switzerland) · 2026Review
- Moyamoya disease in Latin America: A systematic literature review with an illustrative case.Surgical neurology international · 2026Article
- Effects of intravenous dexmedetomidine on hemodynamic stability, inflammatory factors, and brain injury biomarkers in patients with Moyamoya disease undergoing revascularization surgery.American journal of translational research · 2026Article
- Increased plasma fibronectin mirrors intimal phenotypic switching of vascular smooth muscle cells in moyamoya arteriopathy.Scientific reports · 2025Article
- [Epilepsy in Patients With Moyamoya Angiopathy].Revista de neurologia · 2025Article
- Blurred by a "Puff of Smoke"-A Case-Based Review on the Challenging Recognition of Coexisting CNS Demyelinating Disease and Moyamoya Angiopathy.International journal of molecular sciences · 2025Review
- Lipidomic profiling of the cerebrospinal fluid in moyamoya angiopathy patients.Orphanet journal of rare diseases · 2025Article
- Impact of Revascularization Timing on Clinical Outcomes of Symptomatic Moyamoya Disease: A Systematic Review and Multivariate Analysis.Neurosurgery practice · 2025Review
- Relationship Between CNS Infections, Stroke, and Neurological Complications: A Case Series.Cureus · 2025Article
- Navigating Diagnostic Complexities and Treatment Strategies of Moyamoya Syndrome: A Case Report.Cureus · 2024Article
- Leveraging AI to advance surgical outcomes in Moyamoya disease.Neurosurgical review · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya angiopathy (MMA) is a peculiar cerebrovascular condition characterized by progressive steno-occlusion of the terminal part of the internal carotid arteries (ICAs) and their proximal branches, associated with the development of a network of fragile collateral vessels at the base of the brain. The diagnosis is essentially made by radiological angiographic techniques. MMA is often idiopathic (moyamoya disease-MMD); conversely, it can be associated with acquired or hereditary conditions (moyamoya Syndrome-MMS); however, the pathophysiology underlying either MMD or MMS has not been fully elucidated to date, and this poor knowledge reflects uncertainties and heterogeneity in patient management. MMD and MMS also have similar clinical expressions, including, above all, ischemic and hemorrhagic strokes, then headaches, seizures, cognitive impairment, and movement disorders. The available treatment strategies are currently shared between idiopathic MMD and MMS, including pharmacological and surgical stroke prevention treatments and symptomatic drugs. No pharmacological treatment able to reverse the progressive disappearance of the ICAs has been found to date in both idiopathic and syndromic cases. Antithrombotic agents are usually prescribed in ischemic MMA, although the coexisting hemorrhagic risk should be considered. Surgical revascularization techniques, which are currently the best available treatment in symptomatic MMA, are associated with good long-term outcomes and reduced ischemic and hemorrhagic risks. Given the lack of dedicated randomized clinical trials, current treatment is mainly based on observational studies and physicians' and surgeons' expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.